| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.8 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.8 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | -0.0073 | 0.8 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | -0.014 | 0.9 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.0091 | 0.9 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |